Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 337
Rating:

Dr Myriam Chalabi - Netherlands Cancer Institute, Amsterdam, Netherlands

Dr Myriam Chalabi speaks with ecancer at ESMO 2018 in Munich about the first neoadjuvant study of anti-CTLA-4 ipilimumab plus anti-PD1 nivolumab in early stage dMMR and MMR proficient colon cancers.

She links mismatch repair status and response rates observed in 15 tumours, and describes the tolerability as a positive indicator for further research in neoadjuvant immunotherapy for these patients.

Combination immunotherapy for metastatic colorectal cancer (mCRC) is also discussed by Dr Heinz-Josef Lenz here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation